NIPH Clinical Trials Search

UMIN ID: UMIN000000758

Registered date:02/07/2007

Phase III clinical trial for AT-877 (i.v.) in patients with acute ischemic stroke. Placebo-controlled, double-blind add-on therapy to antiplatelet drugs

Basic Information

Recruitment status Complete: follow-up complete
Health condition(s) or Problem(s) studiedAcute ischemic stroke (excluding cardioembolic stroke)
Date of first enrollment2007/06/01
Target sample size770
Countries of recruitmentJapan
Study typeInterventional
Intervention(s)AT-877 120mg/day or placebo Antiplatelet drug


Primary OutcomeDichotomized mRS score
Secondary OutcomeComparison between mRS groups, JSS-M scores

Key inclusion & exclusion criteria

Age minimum20years-old
Age maximumNot applicable
GenderMale and Female
Include criteria
Exclude criteria(1) Patients having a history of coronary, renal, hepatic or metabolic disease. Patients exhibiting dysemia (2) Other conditons at the discretion of the investigator

Related Information


public contact
Name Toshiya Umeda
Address 9-1 Kanda Mitoshiro-cho, Chiyoda-ku, Tokyo, Japan Japan
Telephone 03-3259-5831
Affiliation Asahi Kasei Pharma Corporation Clinical Development Center
scientific contact
Name Norio Tanahashi
Address 1397-1 Yamane, Hidaka-shi, Saitama-ken, Japan Japan
Affiliation Saitama International Medical Center, Saitama University Professor, Dept. of Neurology